Biomarkers to stratify pain severity and type in pancreatic disease

用于对胰腺疾病疼痛严重程度和类型进行分层的生物标志物

• 批准号: 10707763
• 负责人: Jami Lynn Saloman
• 金额: $ 77.81万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10707763
• 关键词: Address; Antibodies; Arthritis; Biological; Biological Assay; Biological Markers; Blood; Calcitonin Gene-Related Peptide; Chronic; Clinical; Cohort Studies; Complications of Diabetes Mellitus; Data; Decision Making; Dedications; Diabetes Mellitus; Disease; Endoscopy; Enrollment; Evaluation; Exocrine pancreatic insufficiency; Fibrosis; Funding; Hand; Home; IL6ST gene; Inflammation; Interstitial Cystitis; Intervention; Knowledge; Leadership; Letters; Malignant neoplasm of pancreas; Maps; Mass Spectrum Analysis; Methods; Monitor; Multiomic Data; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Nerve Growth Factors; Neuropathy; Neuropeptides; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Opioid; Pain; Pain management; Pancreas; Pancreatic Diseases; Pancreatitis; Participant; Patients; Pelvis; Phase; Phenotype; Physicians; Plasma; Plasma Proteins; Platelet-Derived Growth Factor; Proteins; Proteomics; Quality of life; Recurrence; Research Personnel; Resources; Sampling; Sampling Studies; Serum; Set protein; Severities; Site; Symptoms; Syndrome; Testing; Transforming Growth Factor beta; Up-Regulation; Urine; Validation; Visceral pain; acute pancreatitis; biomarker identification; biomarker validation; candidate marker; chemokine; chronic pain management; chronic pancreatitis; clinically relevant; cohort; cytokine; debilitating pain; design; diagnostic criteria; epidemiology study; experience; improved; insight; liquid chromatography mass spectrometry; member; molecular marker; pain relief; patient population; potential biomarker; prospective; secondary analysis; standard of care; success; translational study; treatment response; urinary; validation studies; Address; Antibodies; Arthritis; Biological; Biological Assay; Biological Markers; Blood; Calcitonin Gene-Related Peptide; Chronic; Clinical; Cohort Studies; Complications of Diabetes Mellitus; Data; Decision Making; Dedications; Diabetes Mellitus; Disease; Endoscopy; Enrollment; Evaluation; Exocrine pancreatic insufficiency; Fibrosis; Funding; Hand; Home; IL6ST gene; Inflammation; Interstitial Cystitis; Intervention; Knowledge; Leadership; Letters; Malignant neoplasm of pancreas; Maps; Mass Spectrum Analysis; Methods; Monitor; Multiomic Data; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Nerve Growth Factors; Neuropathy; Neuropeptides; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Opioid; Pain; Pain management; Pancreas; Pancreatic Diseases; Pancreatitis; Participant; Patients; Pelvis; Phase; Phenotype; Physicians; Plasma; Plasma Proteins; Platelet-Derived Growth Factor; Proteins; Proteomics; Quality of life; Recurrence; Research Personnel; Resources; Sampling; Sampling Studies; Serum; Set protein; Severities; Site; Symptoms; Syndrome; Testing; Transforming Growth Factor beta; Up-Regulation; Urine; Validation; Visceral pain; acute pancreatitis; biomarker identification; biomarker validation; candidate marker; chemokine; chronic pain management; chronic pancreatitis; clinically relevant; cohort; cytokine; debilitating pain; design; diagnostic criteria; epidemiology study; experience; improved; insight; liquid chromatography mass spectrometry; member; molecular marker; pain relief; patient population; potential biomarker; prospective; secondary analysis; standard of care; success; translational study; treatment response; urinary; validation studies

PROJECT SUMMARY Chronic pancreatitis (CP) results from progressive inflammation and fibrosis, most commonly from acute pancreatitis (AP) and recurrent episodes of AP (RAP), and is associated with long term complications of diabetes and exocrine pancreatic insufficiency. Pain is one of three diagnostic criteria for AP and multiple studies have now confirmed that pain is also the most significant symptom for patients with CP (77-93%). While there are a variety of interventions available to treat pain, many of which are not efficacious in CP patient: only ~25% chronic pancreatitis patients achieve meaningful pain relief with current standard of care for pain management. As of now, there are no chronic pancreatitis pain biomarkers to stratify pain based on severity and/or type, which would guide physician decision making or monitor therapeutic responses. This contributes to the immense burden of pain in this CP patient population. To address this gap in knowledge, we will leverage the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies (PROCEED) which has been realized under the auspice of the NIDDK-/ NCI-funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). PROCEED, which will be a key resource for this proposal, is the first prospective longitudinal CP cohort in the U.S. It has enrolled 1638 (and counting) participants with CP, AP, and RAP, as well as healthy and non- pancreatitis symptomatic controls. All participants of this unique cohort undergo deep phenotyping, provide detailed information on clinical symptoms, and general QoL variables. Furthermore, 10 pain-associated variables are recorded providing detailed information about pain types, severities and interventions. Due to the size and multi-site nature of PROCEED, the cohort was split into independent discovery and validation cohorts to enable FDA-compliant biomarker validation. In Specific Aims 1 and 2 of this proposal, we will use plasma and urine samples from the PROCEED discovery cohort (n >500) to generate quantitative multi-omics datasets of the proteins, chemokines, cytokines and neuropeptides. Mass spectrometry-based discovery proteomics and multiplexed antibody-based assays will be used for the biomarker identification. Upon discovery of promising pain biomarkers, we will transition to the validation phase (Specific Aims 3 and 4). In this phase, we will use the urine and plasma samples from the independent PROCEED validation cohort (n >500) to validate the potential biomarkers identified in the Specific Aims 1 and 2. We will use targeted liquid chromatography/mass spectrometry methods as well as antibody-based method for the validation. The large number of PROCEED samples and their superb annotation will allow for an exquisitely granular pain-focused analysis of the resulting large scale proteomic and cytokine/chemokine assay data.

项目摘要 慢性胰腺炎（CP）是由进行性炎症和纤维化引起的，最常见于急性 AP（RAP）的胰腺炎（AP）和复发发作，与糖尿病的长期并发症有关 和外分泌胰腺功能不全。疼痛是AP的三个诊断标准之一，多个研究具有 现在证实疼痛也是CP患者（77-93％）的最重要症状。那里 是否可以使用多种干预措施来治疗疼痛，其中许多在CP患者中不有效：只有约25％ 慢性胰腺炎患者通过当前的疼痛护理标准来缓解有意义的疼痛 管理。截至目前，还没有慢性胰腺炎疼痛生物标志物来根据严重程度对疼痛进行分层 和/或类型，这将指导医师决策或监测治疗反应。这有助于 该CP患者人群的痛苦负担很大。 为了解决知识的这一差距，我们将利用对慢性胰腺炎的预期评估 流行病学和翻译研究（继续）已在Niddk-/ NCI资助的财团用于研究慢性胰腺炎，糖尿病和胰腺癌（CPDPC）。 继续是该提案的关键资源，是第一个前瞻性纵向CP队列 美国已招募了1638（且计数）参与者，并接受了CP，AP和RAP，以及健康且不 胰腺炎症状控制。这个独特队列的所有参与者都会进行深层表型，提供 有关临床症状和一般质量变量的详细信息。此外，10个疼痛相关变量 记录了有关疼痛类型，严重性和干预措施的详细信息。由于大小和 继续进行的多站点性质，该队列分为独立发现和验证队列以启用 符合FDA的生物标志物验证。在本提案的特定目的1和2中，我们将使用血浆和尿液 从“继续发现”同类（n> 500）中的样本生成定量的多摩变数据集 蛋白质，趋化因子，细胞因子和神经肽。基于质谱的发现蛋白质组学和 基于多抗体的测定将用于生物标志物识别。 发现有希望的疼痛生物标志物后，我们将过渡到验证阶段（特定目的3和4）。 在此阶段，我们将使用独立进行验证队列中的尿液和血浆样品（n > 500）验证特定目的1和2中确定的潜在生物标志物。我们将使用目标液体 色谱/质谱法以及基于抗体的验证方法。大 进行样本的数量及其出色的注释将允许精致的颗粒状疼痛 分析所得的大规模蛋白质组学和细胞因子/趋化因子测定数据。